Pharmacologic treatments for covid-19 patients

Methods

Protocol

Protocol amendment:

As of March 1, 2022, the COVID-NMA revised its protocol to include only studies evaluating immunomodulators and antiviral therapies. Comparisons evaluating antivirals and immunomodulators will continue to be updated every two weeks.

For treatments that are neither immunomodulators nor antivirals, we provide the updated results up to Feb 28, 2022 including all identified reports through our search strategy up tp this date.

meta-COVID

Perform your own analysis using COVID-NMA data, create and download your forest plots by clicking below:

go to metacovid

Treatment comparisons

Of note, as of March 1, 2022, the COVID-NMA revised its protocol and reduced its scope.
Only comparisons evaluating antivirals and immunomodulators will continue to be updated every two weeks.

Create and download your forest plots with the most up-to-date data here Forest plots

Search by treatment name :

Display new or updated analyses

Display all results

Your research: All results

Access the forest plots for the 350 treatment comparisons .

    Anti-virals (72 comparisons)

    Interferons (13 comparisons)

    Other antimicrobials (antibiotics, antimalarials, antiparasitics) (42 comparisons)

    NSAIDs and Anti-inflammatories (9 comparisons)

    Kinase inhibitor (16 comparisons)

    Corticosteroids (14 comparisons)

    Monoclonal antibodies (72 comparisons)

    Other immunomodulators (11 comparisons)

    Convalescent plasma (4 comparisons)

    Antithrombotic (antiplatelet, anticoagulant, thrombolytic drug) (13 comparisons)

    Other Advanced therapy medicinal products (ATMP) (3 comparisons)

    Others (53 comparisons)

Search studies

Search by Author Registration number

General characteristics of primary studies

Page: 1 / Sorted by: Most recent ↓
Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Treatment 1 Treatment 2
New
NCT04539275
VACURES-1
NCT04539275, Unpublished, 2022
Full text
Not reported/unclear

Convalescent plasma

Placebo

RCT Patients with confirmed COVID-19 (moderate) admitted to 24 centers in the USA. N=75
Some concerns
Details

Full description

New
NCT04678739
Mohiuddin Chowdhury ATM, Front pharmacol, 2022
Full text
Commentary
Not reported/unclear

Tocilizumab + Remdesivir

Dexamethasone

RCT Patients with confirmed COVID-19 (severe) admitted to 3 centers in Bangladesh N=208
Some concerns
Details

Full description

New
CTRI/2021/06/033938
Kumarasamy N, CROI, 2022
Full text
Private

Molnupiravir

Standard care

RCT Outpatients with confirmed COVID-19 (mild) treated in 26 centers in India. N=1218
Some concerns
Details

Full description

New
NCT04345991
CORIPLASM
Lacombe K, Vox Sang, 2022
Full text
Not reported/unclear

Convalescent plasma

Standard care

RCT Patients with confirmed COVID-19 (moderate) admitted to 14 centers in France. N=120
Some concerns
Details

Full description

NCT04647695
Tam A, Clin Infect Di, 2022
Full text
Commentary
Commentary
Public/non profit

Interferon Beta 1b + Remdesivir

Remdesivir

RCT Patients with confirmed COVID-19 (asymptomatic-mild-moderate) isolated and treated at 3 centers in China (Hong Kong SAR). N=212
Some concerns
Details

Full description

CTRI/2021/03/031721
Wadhwa B, medRxiv, 2022
Full text
Commentary
Commentary
Public/non profit

Spironolactone + Dexamethasone

Dexamethasone

RCT Patients with suspected or confirmed COVID-19 (moderate-severe) admitted to a single center in India N=120
High
Details

Full description

IRCT20180302038915N1
Bozorgmehr R, Arch Acad Emerg Med, 2022
Full text
Commentary
Public/non profit

Interferon beta 1a + Sofosbuvir

Interferon beta-1a

RCT Patients with confirmed COVID-19 (severe) admitted to a single center in Iran. N=106
Some concerns
Details

Full description

NCT04790786
OPTIMISE-C19
Huang D, JAMA Netw Open, 2022
Full text
Commentary
Commentary
Mixed

Sotrovimab

Casirivimab+Imdevimab (REGN-COV2)

RCT Outpatients with confirmed COVID-19 (mild) treated at 40 centers in the USA. N=3558
Some concerns
Details

Full description

NCT04885530
ACTIV 6
Naggie S, medRxiv, 2022
Full text
Commentary
Commentary
Mixed

Fluticasone (inhaled)

Placebo

RCT Outpatients with confirmed COVID-19 (mild) treated at 93 centers in the USA. N=1407
Some concerns
Details

Full description

NCT04625114
Tobback E, Int J Infect Dis, 2022
Full text
Commentary
Mixed

Camostat Mesilate

Placebo

RCT Outpatients with confirmed COVID-19 (asymptomatic-mild) treated at a single center in Belgium. N=96
Some concerns
Details

Full description